EU/3/19/2177

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2177 was granted by the European Commission to Bayer AG, Germany, for regorafenib for the treatment of glioma.

Key facts

Active substance
regorafenib
Disease / condition
Treatment of glioma
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2177

Sponsor's contact details

Bayer AG
Kaiser-Wilhelm-Allee 1
Wiesdorf
51373 Leverkusen
Tel. +49 2143 051564
E-mail: clinical-trials-contact@bayer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating